Hepatitis B Annual

Current Issue  

Back Issues   


Search Login    Users online: 62 Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
>>> Ahead of Print <<<
Year : 2008  |  Volume : 5  |  Issue : 1  |  Page : 134-145

Comparison of entecavir and telbivudine in management of chronic Hepatitis B

Department of Gastroenterology, S.C.B. Medical College, Cuttack - 753 007, India

Correspondence Address:
Shivaram Prasad Singh
Department of Gastroenterology, S.C.B. Medical College, Cuttack - 753 007
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0972-9747.58811

Rights and Permissions

The currently available options for the treatment of chronic hepatitis B virus (HBV) infection include standard and pegylated interferon alfa and four oral antiviral agents (lamivudine, adefovir, entecavir, and telbivudine). These treatment strategies are either therapies of finite duration which aim to achieve sustained off-therapy responses or long term treatments that aim to maintain on-therapy remission. Most agents designed to target hepatitis B are hindered by the development of resistance, poor tolerability or limited efficacy; therefore, new agents and treatment strategies are needed. Pegylated interferon alfa may offer higher sustained off-therapy responses after one year, but most patients do not respond. Oral antivirals are the only candidates for long term treatment of patients with chronic HBV infection. Viral suppression has favorable effects on outcome outcome and modifies the natural history of the disease. The oral nucleos(t)ide analogues are generally better tolerated than interferon. This article attempts to provide an overview of the data available on the two new drugs entecavir and telbivudine.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded449    
    Comments [Add]    

Recommend this journal